Solventum Corp (SOLV) Stock
Key stats
- Market cap
- $15.06B
- Price / Earnings ratio
- 98.0x
- EPS (TTM)
- $0.89
- Volume
- Loading
- 52-week high
- $94.16
- 52-week low
- $62.38
- EPS vs analyst estimate
- +4.9%Q3 FY25 · $1.50 vs $1.43
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with SOLV
Recent news

SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
SOLV

Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SOLV

Here's Why Solventum (SOLV) is a Strong Value Stock
Here's Why Solventum (SOLV) is a Strong Value Stock
SOLV

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
SOLV
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.21
- MACD 12/26/9
- 0.58
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.69
- SMA 50
- $87.65
- Price above SMA 50
- EMA 50
- $86.73
- Price above EMA 50
- SMA 200
- $78.72
- Price above SMA 200
- EMA 200
- $81.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.65 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
SOLV

Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SOLV

Here's Why Solventum (SOLV) is a Strong Value Stock
Here's Why Solventum (SOLV) is a Strong Value Stock
SOLV

SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
SOLV

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
SOLV

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV

Here's Why Solventum (SOLV) is a Strong Value Stock
Here's Why Solventum (SOLV) is a Strong Value Stock
SOLV

Why Solventum (SOLV) is a Top Stock for the Long-Term
Why Solventum (SOLV) is a Top Stock for the Long-Term
SOLV

Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
SOLV

Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
SOLV
News tone: automated (AI) classification of the article's content, not a price prediction.
About Solventum Corp
Solventum is a global healthcare solutions company that develops, manufactures, and commercializes a range of products for the medical, dental, and health information industries, leveraging material science, data science, and digital capabilities
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 1967 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 1970 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 1975 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 1967 |
| Ms. Heather L. Knight | Chief Commercial Officer | 1972 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 1976 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | — |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 1970 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 1973 |
| Mr. Paul S. Harrington | Chief Supply Chain Officer | 1970 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.21
- MACD 12/26/9
- 0.58
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.69
- SMA 50
- $87.65
- Price above SMA 50
- EMA 50
- $86.73
- Price above EMA 50
- SMA 200
- $78.72
- Price above SMA 200
- EMA 200
- $81.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $95.00
- Average
- $100.00
- High
- $110.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -13.1 | -5.9 | -8.9 | -7.3 | +14.4 | +10.4 | +9.2 | +7.8 | -1.3 | -8.2 | ||
| 2025 | +12.3 | +8.4 | -5.1 | -13.4 | +11.4 | +3.7 | -8.4 | +1.9 | +1.6 | -5.5 | +25.2 | -7.4 |
| 2026 | -2.6 | -3.5 | -10.5 | +4.7 | +12.5 | +1.7 | +9.0 | +3.4 | -3.1 | -7.3 | +4.6 |



